Radisys Announces Availability of Industry-first Release 17 Compliant 5G NR Solution
22.2.2023 16:00:00 EET | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, today announced its Release 17 compliant 5G NR software solution, extending its award-winning Release 16 Software with advanced features like non-terrestrial networks (NTN) and integrated access and backhaul (IAB) that expands coverage ability for 5G Networks. Release 17 relay node and satellite access capabilities will improve worldwide cellular service availability by enhancing the accessibility of fast and reliable 5G connectivity for unserved and underserved areas. In addition to driving ubiquitous 5G consumer access, Radisys’ Release 17 compliant 5G NR software supports enterprise, infrastructure and public safety use cases including intelligent transportation systems (ITS), aeronautic broadband, maritime, critical communications, fleet management, smart factories, and Internet of Things (IoT) devices.
Radisys’ Connect RAN 5G solution facilitates a flexible 5G network to meet varied deployment requirements and provide universal 5G connectivity for diverse applications and use cases. By deploying Connect RAN 5G software, customers can minimize their development costs and operational and capital expenses while at the same time improving time-to-market and shortening their return on investment.
News Highlights
- Radisys’ Release 17 compliant RAN software continues its proven track record of 5G R&D innovation, enabling 5G Network connectivity for diverse service enabler ultra-reliable low latency communication (URLLC), and eMBB use cases across a wide set of FR1and FR2 bands for multiple deployment and access options.
- Radisys’ Connect RAN 5G software’s NTN feature supports geostationary, medium and low earth orbit (GEO/MEO/LEO) satellite access with flexible and scalable software architecture and well-defined interfaces to SATCOM infrastructure. Radisys’ NTN software empowers OEMs and ODMs to unlock newer business opportunities by leveraging the significant investment being made in SATCOM technology.
- Radisys’ IAB feature enhances centralized (CU) and distributed (DU) units to service relay nodes as 3GPP compliant Donor CUs and Donor DUs. It also includes IAB/Relay node comprising IAB-DU and IAB-MT software that provides end-to-end IAB solution integration with industry-leading platforms.
- Radisys’ Release 17 compliant RAN software provides a foundation for features such as NR positioning, reduced capability (RedCap), and NR SideLink enabling OEMs, ODMs and operators to cost-effectively scale their 5G networks.
“We are excited to launch the first-to-market Release 17 Connect RAN 5G Software delivering expanded 5G connectivity and service accessibility, enabling our customers to unlock newer business opportunities,” said Munish Chhabra, SVP and General Manager, Software and Services, Radisys. “With advanced features like NTN and IAB, Radisys continues to be a leader in delivering ORAN-compliant multi-architecture and multi-platform 5G software to our customers, driving business use cases across a variety of industry verticals.”
Meet with Radisys at MWC Barcelona
See demonstrations of Radisys’ industry-first Release 17 compliant 5G NR Solution, at MWC Barcelona, Stand 5B81. To schedule a meeting with Radisys’ mobility experts, contact open@radisys.com.
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005290/en/
Contact information
Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom